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SUMMARY 
Background: To investigate IOP control following 
twelve months of continuous medical therapy in Gha-
na. 
Methods: This retrospective case series included 163 
glaucoma patients diagnosed at a referral eye center 
between 1996 and 2006. Information collected includ-
ed age, gender, IOP at presentation, six months and one 
year post treatment and types of anti-glaucoma medica-
tions prescribed. Optimal IOP control was defined ac-
cording to results from the Advanced Glaucoma Inter-
vention Study (AGIS), which demonstrated arrest of 
visual field progression in patients with IOP < 18 
mmHg at all visitations: Level 1 (post-treatment IOP ≤ 
21 mmHg); Level 2 (≤ 18 mmHg) and level 3 (≤ 16 
mmHg). The principal outcome measure was the 
achievement of IOP <18 mmHg at six months and 
twelve month visitations.  
Results: One hundred sixty three patients were ana-
lyzed. These included 68 males (41.7%) and 95 fe-
males (58.3%). The mean age was 57±16 (median 59 
years; range 7 – 95 years). There was no significant 
difference in age (p=0.35) or mean IOP (p=0.08) be-
tween genders. The mean pre-treated IOP of 31.9±8.9 
mmHg significantly decreased to 21.3±6.6 mmHg at 6 
months (p=0.001), with 57.4% of eyes at Level 1 IOP 
control, 25.3% at Level 2 and 15.4% at Level 3 and 
decreased further at 12 months to 20.7±6.9 mmHg 
(p=0.48) with 69.7% of eyes at Level 1, 34.4% at Level 
2, and 12.4% at Level 3. 
Conclusions: Current medical regimen is insufficient 
to reduce IOP to target levels as defined in the Ad-
vanced Glaucoma Intervention Study.  
 






Glaucoma is the second most important cause of blind-
ness in Ghana surpassed only by cataract.1 It is estimat-
ed to account for 20.6% of all causes of blindness in 
the country.2 Blindness from the disease, unlike that of 
cataract, is irreversible making it the most common 
cause of irreversible blindness. Worldwide the disease, 
in its various forms affects some 66.8 million people 
out of which 6.7 million are presumed blind from it.3 
Primary open angle glaucoma (POAG) is the most 
common variant in Africa and has been shown in Black 
populations to have an earlier onset and run a more 
aggressive course.4 This variant is reported to affect 
nearly one out of every ten (8.5%) people aged 40 
years and above living in Ghana.5  Medical therapy 
aimed at reducing the intraocular pressure (IOP) is the 
primary treatment for POAG, however it is unknown if 
medical therapy alone is sufficient to achieve target 
levels in Ghanaian patients.  
 
The Advanced Glaucoma Intervention Study (AGIS) in 
particular demonstrated that lower IOP is associated 
with reduced progression of visual field defect. AGIS 
found that eyes with 100% of visits with IOP <18 
mmHg over 6 years had mean changes from baseline in 
visual field defect score close to zero during follow-up, 
whereas eyes with less than 50% of visits with intraoc-
ular pressure less than 18 mm Hg had an estimated 
worsening over follow-up of 0.63 units of visual field 
defect score (P =.083).6 Using the results from AGIS as 
a benchmark for successful IOP control, we developed 
the first study to investigate the outcome of medical 













MATERIALS AND METHODS 
Study Design 
A retrospective case series involving the review of 
clinical records of all ‘first-time’ glaucoma cases treat-
ed at the Emmanuel Eye Centre, Accra, Ghana between 
1996 and 2006. Information collected included age, 
IOP documented at presentation, six months and one 
year; and types of anti-glaucoma medications given at 
presentation, six months and one year to achieve IOP 
control. In all 163 patients were reviewed. All patients 
were of African descent, older than 18 years of age, 
and presented with elevated IOP (IOP >21 mmHg as 
measured with Goldmann applanation tonometry).   
 
Case Definition and Diagnosis 
Case definitions were based on the working protocol 
used in the clinic. Glaucoma was diagnosed by the 
finding of a characteristic optic disc excavation (glau-
comatous cupping) in the presence of elevated IOP 
with or without matching visual fields and no second-
ary cause of glaucoma identified. Ocular hypertension 
(OHT) was defined as persistent presenting IOP higher 
than 21 mmHg in the absence of ocular hypotensive 
medications and optic nerve head damage. Optic disc 
evaluations, as is the practice of the hospital, were all 
done with either the Volk 78 or 90 Diopter condensing 
lenses. All the cases were diagnosed and managed by 
experienced ophthalmologists and all IOPs were meas-
ured using the slitlamp-mounted Goldmann applana-
tion tonometer. 
 
Inclusion and Exclusion Criteria 
Only untreated cases that received their required medi-
cations from the clinic and were followed up to one 
year with IOPs measured at times of visitations were 
included in the study. All cases of true congenital and 
secondary glaucoma were excluded. Also excluded 
were patients who had had glaucoma filtering surgery, 
glaucoma-specific laser procedures or patients with 
medically controlled IOPs (prior to first visitation). We 
elected not to include records of angle closure glauco-
ma due to the different mechanism of elevated IOP in 
this disease. 
 
Principal Outcome and Measure of Success 
The principal outcome of interest was the IOP, meas-
ured at presentation, six months and at twelve month 
visits. Successful IOP control was defined using three 
levels of success designed by our team and based in 
part on results from the Advanced Glaucoma Interven-
tion Study (AGIS). With this information, we designed 
three levels of IOP control for subjects in this study: 
Level 1 (borderline control), where the mean post-
treatment IOP was measured at 21 mmHg or less at the 
time of visit; Level 2 (moderate control), where the 
mean IOP was measured at 18 mmHg or lower; and 
level 3 (high control), at 16 mmHg or lower. 
 
Drug Administration 
As a clinical protocol in this facility, all first-time un-
treated POAG or OHT patients presenting with IOPs of 
30mmHg or higher were prescribed two medications, 
the type of which depended on a number of factors that 
related to both the patient and facility. The most im-
portant facility factor was the availability of the pre-
scribed medication at the time of presentation. Where 
this was unavailable, a drug prescription form was giv-
en to the patient to purchase from a pharmacy shop. 
Patient factors in regards to treatment efficacy there-
fore included one’s ability to pay for the prescribed 
medications or known adverse reactions to the drug or 
similar agents. For example, patients who reported an 
allergy to sulphonamides were not prescribed acetazo-
lamide preparations. In this current study, only patients 
who received all their required medications from the 
hospital were enrolled into the study.  
 
Types of anti-glaucoma drugs prescribed in this hospi-
tal setting covered nearly the entire spectrum of com-
monly used ocular anti-hypertensive topical medica-
tions. These included emerging drugs (at that time) like 
prostaglandin analogues, prostamides and fixed combi-
nation preparations. 
 
From the reviewed clinical notes, no specific target 
pressures were set for any of the patients, however the 
doctors sought to control the pressures to the so-called 
‘normal pressure’ of 21mmHg, which is currently 
known to be inadequate in forestalling disease progres-
sion.6 Once a patient failed to achieve this end-point, 
the medications were modified by adding new ones, 
substituting existing ones or by doing both.  
 
Data Analysis 
Data were entered and checked using Microsoft Ex-
cel©.  Epi Info™ 3.4.1 and Stata™ 8.1 were used for 
the analysis; these two tools were complimentary. For 
continuous variables, the mean and the standard devia-
tion were reported and where necessary, the median 
was also reported. For continuous variables with two 
groups, the Student’s t-test was used while the one-way 
analysis of variance (ANOVA) was employed for more 
than two groups. Where multiple comparisons were 
done, the Bonferroni Correction was applied.  All sta-
tistical tests were two-sided and an alpha level < 0.05 
was considered a statistically significant result. The 
95% confidence intervals and Fisher's exact test for 











In all, records of 163 patients with either OHT or 
POAG were analyzed. These were made up of 68 
males (41.7%) and 95 females (58.3%). The mean age 
of the studied population was 57±16 with a median of 
59 and a range of 7 to 95 years. The mean pre-
treatment IOP was 31.9±8.9 mmHg. This was slightly 
higher in males (32.9±9.2 mmHg) compared to females 
(31.2±8.7 mmHg), but this difference was not statisti-
cally significant (p=0.08). 
 
IOP Trend Analysis 
Successful IOP control was defined using three levels 
of success designed by our team and based in part on 
results from the AGIS study which provided clear evi-
dence that low IOP is associated with reduced progres-
sion of visual field defect.6 There was a significant 
drop in the presenting mean IOP from the baseline val-
ue of 31.9±8.9 mmHg to the 6th month value of 
21.3±6.6 mmHg and a further drop to the 12th month 
value of 20.7±6.9 mmHg following treatment. While 
changes from baseline IOP at initiation of treatment to 
the 6 month mark were statistically significant 
(p=0.001), there was no significant change noticed in 
IOPs between the sixth and twelve month (p=0.48). 
 
Regarding IOP control, at the 6 month mark, 57.4% of 
the studied eyes had their IOPs controlled to a level 
≤21 mmHg. Approximately one in every four patients 
(25.3%) were controlled to <18 mmHg and only 15.4% 
were controlled to <16 mmHg after continuous medical 
therapy. By the 12th month, 69.7% were controlled to 
≤21 mmHg, 34.4% were controlled to <18 mmHg and 
only 12.4% were controlled to <16 mmHg. These re-
sults are graphically displayed in Figure 1.  
 
Mean pre-treatment IOP of 31.9±8.9 mmHg decreased 
to 21.3±6.6 mmHg at 6 months (p=0.001), with 57.4% 
of the eyes at Level 1 (borderline control), 25.3% at 
Level 2 (moderate control), and 15.4% at Level 3 (high 
control), and decreased further at 12 months to 
20.7±6.9 mmHg (p=0.48) with 69.7% of the eyes at 
Level 1, 34.4% at Level 2, and 12.4% at Level 3. 
 
Anti-glaucoma Drug Prescription Patterns 
The mean number of prescriptions patients were placed 
on at their initial diagnosis was calculated at 1.6±0.65 
medications. This increased to 1.9±0.77 medications at 
the 6th month and 1.9±0.75 medications by the 12th 
month. Patients were placed on either one (42.3%) or 
two (47.5%) topical eye medications initially. As 
shown in Table 1, with time a higher percentage of 
patients were prescribed additional medications to 
achieve IOP control. Table 2 shows the percent distri-
bution of medications prescribed across the period of 
this study. The most common medication prescribed 
was a topical beta blocker followed by a carbonic an-
hydrase inhibitor (CAI). 
 
 
Figure 1 Stratification of IOP control at 6 and 12 
month intervals 
 
Table 1 Pattern of anti-glaucoma drug prescriptions 
Drugs At Presentation Month 6 Month 12 
 No. % No. % No. % 
1 129 42.3 96 29.5 92 28.3 
2 145 47.5 157 48.3 159 48.9 
3 31 10.2 64 19.7 68 20.9 
4 0 0 8 2.5 6 1.8 
 
Table 2 Anti-glaucoma drugs prescribed 
Drug Type  At Presentation Month 6  Month 12 
Beta blockers  45.6 47.7 49.6 
CAIs  28.1 22.6 22 
Parasympathomimetics  
(Pilocarpine)  
17.4 18 17.6 
Prostaglandins and 
Prostamides  
6.8 7.4 8.8 
Alpha agonists  0.9 1.7 0.6 
Fixed combinations  0.9 0 0 
Others  <1 2.6 1.7 
Total 100 100 100 
 
DISCUSSION 
This study investigated outcomes of medical therapy in 
Ghanaian patients and found that an unsatisfactory 
percentage of patients achieved AGIS IOP criteria 
demonstrated to arrest visual field progression.6 Persis-
tent elevation in the IOP has been identified as the 
most important risk factor for the development and 
progression of glaucoma.6,8,7 The findings from this 
study provide, for the first time in Ghana, clear evi-
dence that medical therapy alone is insufficient for 
adequate control of IOP.  
 
 




Reports from the AGIS Study show that patients who 
had their IOP controlled by laser or filtering surgery 
after failed medical treatment had slower progression 
in visual field (VF) deterioration.6  In this study, eyes 
receiving medical treatment were categorized accord-
ing to target IOPs into borderline control (Level 1, ≤21 
mmHg), moderate control (Level 2, <18 mmHg) and 
high control (Level 3, <16 mmHg) with only 34.4% of 
the studied eyes achieving the 18 mmHg cut-off identi-
fied in the AGIS.6 In the best performing category, 
(borderline control) the proportion of eyes that 
achieved the required cut off IOP (69.7%) was still 
much lower than those achieved by comparative inter-
ventions like trabeculectomy. Verrey et al previously 
reported in a retrospective study in Ghana that 84% of 
patients treated with trabeculectomy achieved target 
IOP levels at 6 months versus only 17% of medical 
treated pateints.8 In the British national survey of tra-
beculectomy techniques, the overall level of unquali-
fied success (IOP control of <21 mmHg without addi-
tional medication) was measured at 84% and qualified 
success (with medication) at 92% after a duration of 1 
year.9 Similarly high success rates have been found in 
other studies among Black West African populations.10, 
11 
 
To the best of our knowledge, no prior study in Ghana 
has investigated the medical treatment as a sole mo-
dality for achieving AGIS target levels for IOP. The 
baseline IOP value reported in this study of 31.9 
mmHg to the 6th month value of 21.3 mmHg does not 
appear sufficient for adequate POAG control. Further-
more, no statistical difference in IOP was reported at 
the twelve-month visitation despite an increase in ocu-
lar hypotensive medication administration. 
 
Our results agree with Verrey et al, who reported that 
only 17% of patients treated medical had an IOP less 
than 22 mmHg at six-month follow-up, but this study 
did not extend follow up beyond six-months and did 
not have the benefit of newer medications or the more 
recent randomized trials.8 Francis et al compared ad-
vanced and moderate glaucoma patients and reported 
that advanced glaucoma patients presented with a mean 
IOP on first presentation greater than 30 mmHg in both 
eyes (OD: 30.93; OS: 32.37 mmHg), but treatment 
effects were not analyzed.12 Ntim-Amponsah et al in-
vestigated risk factors for glaucoma progression and 
reported that initial IOP>31 mmHg was associated with 
advanced glaucoma at presentation, but also did not 
investigate the effects of medical treatment.13  
 
The poor measure of control among study subjects in 
this study is unlikely to be a result of low efficacy of 
the various medications used to reduce IOP. The effec-
tiveness of the most commonly used drugs have been 
extensively studied and used in the major glaucoma 
clinical trials with good outcomes in reducing IOP.6, 7 
Topical beta blockers, for example, were used exten-
sively in the Ocular Hypertension Treatment Study 
(OHTS)14 and the EMGT.7  
 
In addition almost all the patients were on multiple 
medications and the number of drugs used increased as 
the disease progressed. The mean number of drugs 
initially prescribed was 1.6±0.65 and this increased to 
1.9±0.77 by the 12th month.  
 
A more likely explanation for such a high treatment 
failure may be related to compliance rather than drug 
efficacy as most of the drugs used had both interna-
tional and local regulatory body’s approval. In one 
systematic review, Olthoff and co-workers measured 
medical treatment non-compliance among glaucoma 
patients to range from 5% to as high as 80%.15 Using 
qualitative study methodologies, Lacey and coworkers 
identified multiple barriers to anti-glaucoma medica-
tion compliance among patients in the UK.16 Similar 
studies relating to compliance have been extensively 
studied in the United States.17, 18 In one such study, 
Tsai and co-workers identified as many as 71 barriers 
to medication compliance and subsequently catego-
rized these into 4 groups: Situational/environmental 
factors (49%), Medication regimen (32%),  Patient 
factors (16%) and Provider factors (3%).17 
 
This study did not look into barriers to treatment ad-
herence among subjects and the authors do not intend 
to make any authoritative statement on this subject. On 
the other hand, the issue of limited patient education, 
low doctor/patient ratios in sub-Saharan African na-
tions like Ghana and the absence of counseling on 
glaucoma eye drop application techniques cannot be 
overemphasized. Ghana’s population now exceeds 24 
million people with only 52 ophthalmologists in active 
clinical practice (19 million and 45 ophthalmologists 
respectively as of the most recent National Eye Care 
Report in 2004).19 This is compounded by the absence 
of nurses and other health care professionals specifical-
ly trained to educate and counsel the glaucoma patient.  
 
Limitations of this study include the retrospective de-
sign, the small number of patients enrolled and the in-
volved of only a single large tertiary care center. Cor-
neal pachymetry was not available at this clinic and 
diurnal variations in IOP were not measured, however 
a recent study investigating CCT in Ghana by Ntim-
Amponsah et al demonstrated an average CCT of 
524.28 µm for right eyes and 524.70 µm for left eyes in 
253 cases of high tension glaucoma which would ap-
pear to support our Goldmann applanation measure-
ments were not seriously affected by thinner corneas.20  
 
 





The patient population was homogenous in their base-
line demographics, however medical comorbidities that 
may affect IOP (diabetes, hypertension, myopia, inher-
ited disease) were not recorded. This study did not at-
tempt to correlate achievement of IOP level with pro-
gression or no progression of clinical disease as meas-
ured by visual field analysis, optic nerve imaging, or 
visual acuity and these results were therefore not in-
cluded. This study did not attempt to define a threshold 
for progression using visual field data due to the single 
center and relatively small patient sample. Also taken 
into consideration was the low likelihood of demon-
strating significant changes in visual fields within the 
short study period of one year. We also chose not to do 
comparative analysis on the effects of the various anti-
glaucoma medications as medications prescribed were 
often in combination and patient surveys were not 
available for this retrospective study.  Patients were not 
stratified by baseline IOP given the elevated mean IOP 
for all subjects and the percent reduction of IOP for 
each patient likely varied.  
 
CONCLUSION 
In conclusion, the current medical regimen is insuffi-
cient to reduce IOP to levels needed to control disease 
progression in all Ghanaian patients receiving care.  
We suggest that all ophthalmologists be trained to per-
form safe and effective glaucoma surgical procedures 
when medical treatment fails to achieve target goals. 
Patient education and counseling, we suggest, should 
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